Aura Biosciences stock rating maintained at outperform by Citizens
Citizens maintained an Outperform rating and $15.00 price target for Aura Biosciences (AURA), citing progress in its Phase 3 CoMpass trial. The stock, trading at $7.66, has 100% upside potential. Citizens estimates a 60% trial success probability. H.C. Wainwright lowered its target to $18 but kept a Buy rating. AURA has more cash than debt, supporting its clinical programs. The company plans investor updates on choroidal melanoma and expects trial data in late 2027.
How this was made
The 30-second read
Why it matters
The reaffirmed Outperform rating and $15 price target provide a clear catalyst for short‑term buying interest.
Market read
Analyst endorsement may drive near‑term buying pressure on AURA.
What to watch
Potential competition and reimbursement uncertainties for choroidal melanoma therapy.
Background
Aura Biosciences is a clinical-stage biotech developing vision‑preserving therapy for choroidal melanoma; the Phase 3 CoMpass trial is on schedule.
Ticker impact
Citizens reaffirmed an Outperform rating and raised the price target to $15, citing progress in the Phase 3 CoMpass trial.
likely upward pressure as investors price in the new $15 target versus current $7.66 price
The rating and target are fresh analyst actions; the stock is trading well below the target, indicating room for rally.
Market effects
Positive sentiment may spill over to other biotech firms with late-stage trials.
Limited to US-listed biotech sector.
Modest; primarily affects investors tracking US biotech equities.
Counterpoint
The trial still faces execution risk; the target may be overly optimistic.
Key entities
- analystCitizens
Equity research firm that issued the rating and target.
